ADAPTIVE BIOTECHNOLOGIES (ADPT)
US00650F1093 - Common Stock
Taking everything into account, ADPT scores 2 out of 10 in our fundamental rating. ADPT was compared to 56 industry peers in the Life Sciences Tools & Services industry. ADPT has a bad profitability rating. Also its financial health evaluation is rather negative. ADPT is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
ADPT had negative earnings in the past year.
In the past year ADPT has reported a negative cash flow from operations.
ADPT had negative earnings in each of the past 5 years.
ADPT had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -34.96%, ADPT is doing worse than 75.00% of the companies in the same industry.
Looking at the Return On Equity, with a value of -87.25%, ADPT is doing worse than 83.93% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -34.96% | ||
| ROE | -87.25% | ||
| ROIC | N/A |
ROA(3y)-26.63%
ROA(5y)-20.12%
ROE(3y)-50.16%
ROE(5y)-36.47%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ADPT has a better Gross Margin (58.46%) than 80.36% of its industry peers.
In the last couple of years the Gross Margin of ADPT has declined.
The Profit Margin and Operating Margin are not available for ADPT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 58.46% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-10.32%
GM growth 5Y-2.96%
2. Health
2.1 Basic Checks
ADPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ADPT has been increased compared to 1 year ago.
ADPT has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ADPT has a worse debt to assets ratio.
2.2 Solvency
ADPT has an Altman-Z score of -1.66. This is a bad value and indicates that ADPT is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of ADPT (-1.66) is worse than 83.93% of its industry peers.
A Debt/Equity ratio of 0.59 indicates that ADPT is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.59, ADPT is doing worse than 64.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.59 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.66 |
ROIC/WACCN/A
WACC12%
2.3 Liquidity
ADPT has a Current Ratio of 3.52. This indicates that ADPT is financially healthy and has no problem in meeting its short term obligations.
ADPT has a Current ratio (3.52) which is comparable to the rest of the industry.
ADPT has a Quick Ratio of 3.38. This indicates that ADPT is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 3.38, ADPT is doing good in the industry, outperforming 62.50% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.52 | ||
| Quick Ratio | 3.38 |
3. Growth
3.1 Past
ADPT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 14.71%, which is quite good.
The Revenue has decreased by -1.35% in the past year.
Measured over the past years, ADPT shows a very strong growth in Revenue. The Revenue has been growing by 25.04% on average per year.
EPS 1Y (TTM)14.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.14%
Revenue 1Y (TTM)-1.35%
Revenue growth 3Y20.06%
Revenue growth 5Y25.04%
Sales Q2Q%22.46%
3.2 Future
Based on estimates for the next years, ADPT will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.47% on average per year.
Based on estimates for the next years, ADPT will show a quite strong growth in Revenue. The Revenue will grow by 15.10% on average per year.
EPS Next Y17.59%
EPS Next 2Y14.45%
EPS Next 3Y14.47%
EPS Next 5YN/A
Revenue Next Year2.82%
Revenue Next 2Y10.54%
Revenue Next 3Y15.1%
Revenue Next 5YN/A
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ADPT. In the last year negative earnings were reported.
Also next year ADPT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ADPT's earnings are expected to grow with 14.47% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.45%
EPS Next 3Y14.47%
5. Dividend
5.1 Amount
No dividends for ADPT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ADAPTIVE BIOTECHNOLOGIES
NASDAQ:ADPT (12/18/2024, 5:47:51 PM)
After market: 5.85 -0.12 (-2.01%)5.97
-0.55 (-8.44%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap881.05M
Analysts
Price Target
Short Float %
Short Ratio
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -34.96% | ||
| ROE | -87.25% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 58.46% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.32
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.59 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.52 | ||
| Quick Ratio | 3.38 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)14.71%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y17.59%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-1.35%
Revenue growth 3Y20.06%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y